AIDS Drugs Pricing Plans For Poor Nations May Preclude Legislation
This article was originally published in The Pink Sheet Daily
Executive Summary
International AIDS Conference is met with announcements from manufacturers of expanded access in developing nations and a renewed call from Sen. Leahy (D-Vt.) for action on his mandatory licensure bill.
You may also be interested in...
Technology Transfers To Least-Developed Countries Often Not An Option - IFPMA Report
HONG KONG - The transfer of technology developed by high-end research-based pharmaceutical companies to operations in developing countries is increasingly common, but rarely simple
Abbott Cuts Kaletra Price In 40 Countries
Abbott announced April 10 that it would cut the price of its HIV therapy Kaletra (lopinavir/ritonavir) in more than 40 developing countries to around $1,000 per patient annually
Abbott Cuts Kaletra Price In 40 Countries
Move follows spat between firm and Thailand over country’s decision to allow generic HIV therapies.